XRXuan Rao

Xuan Rao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuan Rao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Qian-Qian Wu

    Department of Gynecologic Oncology, Women’s Hospital, School of Medicine Zhejiang University, Hangzhou, China

    1 shared publication
  • Ruizhe Chen

    Medical center for cervical diseases, Women’s Hospital, Zhejiang University School of Medicine

    1 shared publication
  • Xiao Li

    Department of Gynecologic Oncology, Women’s Hospital, School of Medicine Zhejiang University, Hangzhou, China

    1 shared publication
  • Xiao-Fei Zhang

    Department of Pathology, Women’s Hospital, School of Medicine Zhejiang University, Hangzhou, China

    1 shared publication
  • Xinyu Wang

    Zhejiang University, Hangzhou, China

    1 shared publication
  • Yue-Han Wang

    Department of Gynecologic Oncology, Women’s Hospital, School of Medicine Zhejiang University, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Risk-based triage strategy by extended HPV genotyping for women with ASC-US cytology

    by Xuan Rao, Yue-Han Wang, Rui-Zhe Chen, Qian-Qian Wu, Xiao-Fei Zhang, Yun-Feng Fu, Xin-Yu Wang, Xiao Li

    We attempted to evaluate the immediate high-grade squamous intraepithelial lesion-cervical intraepithelial neoplasia grade 2/3 or worse (HSIL-CIN2+/3+, hereafter referred to as CIN2+/3+) risk of specific human papillomavirus (HPV) genotype and form the precise risk-based triage strategy for atypical squamous cells of undetermined significance (ASC-US) women. The clinical data of ASC-US women who underwent HPV genotyping testing and colposcopy were retrospectively reviewed. The distribution and CIN2+/3+ risks of specific HPV genotype were assessed by three approaches. The risk-based triage strategy was further established, and its efficacy in detecting CIN2+/3+ was estimated. Totally, 5553 ASC-US women including 3648 HPV-positive and 1905 HPV-negative were analysed. CIN2+/3+ were 662/319 cases, including 639/306 HPV-positive and 23/13 HPV-negative women. HPV16, HPV52, HPV58 and HPV18 were always among the top 5 ranking genotypes, no matter in HPV-positive women or in HPV-positive CIN2+/3+ cases. HPV16 and HPV33 carried the highest risk, while HPV73 and 26 carried the least risk for CIN2+/3+. Based on the immediate CIN2+/3+ risk of specific HPV genotype, 18 HPVs were divided into three risk-stratified groups. Only women infected with HPVs included in group A were necessary for immediate colposcopy. Compared with conventional strategy, this new risk-based strategy not only had higher specificity (CIN2+: p = .00; CIN3+: p = .01) and positive predictive value (CIN2+: p = .00; CIN3+: p = .03) for detecting CIN2+/3+, but also needed fewer colposcopies to identify each CIN2+/3+. A new triage strategy for ASC-US women was successfully constructed based on CIN2+/3+ risks of 14 high-risk and 4 intermediate-risk HPVs, which could significantly reduce unnecessary colposcopies.